



Current Scenario and Future Prospects of HIV Vaccines

Venkateswarlu Chamcha*

University of Louisiana, USA

Editor's Note

Although several vaccine regimens and trials have been tested for HIV/AIDS at pre-clinical level, only one vaccine trial, i.e., RV144 showed only modest ~30% protection in human clinical trials. Current efforts to prevent HIV have been very optimistic as these efforts reduced the new infections occurring every year from ~2 million/year in 2014 to 1.2 million in 2015. Although, the possibility of achieving a successful HIV vaccine lies elusive, recent breakthroughs had been very promising. On the other hand, therapeutic approaches using more advanced regimen of ART and more recently ART complemented with anti- $\alpha 4\beta 7$ treatments have showed significant impact in controlling the viral burden in infected patients. Furthermore, treating the co-infected patients with specific symptomatic treatments along with ART, have been very successful in controlling if not curing HIV viremia.

In this Issue

Keeping up with the most recent research in the similar lines, in the current issue, we covered wide range of concurrent research topics. First of all, we brought up a case report on limbic encephalitis and chronic inflammatory demyelinating polyradiculopathy at HIV seroconversion stage [1]. We also covered two very informative review

articles on current scenario and future prospects of HIV vaccines and the other being a report from a workshop held in Rome [2,3]. Other research articles will cover wide range of therapies and socio-cultural-cognition in disease progression, are some of the current burning HIV/AIDS related research aspects [4,5]. Overall, this issue attracts wide range of readership and hope will be very informative to you.

References

1. de Oliveira FTM, Júnior FPPL, Esteves A, Modenesi CA (2016) Limbic encephalitis and chronic inflammatory demyelinating polyradiculopathy at HIV seroconversion stage. *J AIDS Clin Res* 7: 625.
2. Ajbani SP (2016) HIV vaccine development: Current scenario and future prospects. *J AIDS Clin Res* 7: 626.
3. Ensoli B, Cafaro A, Amicosante M, Andrieu JM, Boyer JD, et al. (2016) Old and new concepts and strategies in HIV vaccinology: A report from a workshop held in Rome on 17 June 2016. *J AIDS Clin Res* 7: 634.
4. Chaka TE, Abeya SG, Adlo AM, Abebe TW, Hamuse SD, et al. (2016) Antiretroviral therapy: Level of adherence and its determinants among patients on treatment in different health facilities. A cross sectional study in Oromia Regional State, Ethiopia. *J AIDS Clin Res* 7: 629.
5. Munsami A, Mitchell C, Lachenicht L, Kvalsvig JD, Kjetland EF, et al. (2016) The role of socio-cultural-cognition in disease prevalence and risky behaviour among children: A conceptual framework. *J AIDS Clin Res* 7: 631.

***Corresponding author:** Dr. Venkateswarlu Chamcha, Ph.D., Department of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA 30329; Tel: 404 727 1432; Fax: 404 727 7768; E-mail: vchamch@emory.edu

Received December 16, 2016; **Accepted** December 17, 2016; **Published** December 24, 2016

Citation: Chamcha V (2016) Current Scenario and Future Prospects of HIV Vaccines. *J AIDS Clin Res* 7: e125. doi: [10.4172/2155-6113.1000e125](https://doi.org/10.4172/2155-6113.1000e125)

Copyright: © 2016 Chamcha V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.